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“For I know the plans 
 I have for you,” declares the Lord,  
“plans to prosper you and not to harm you,  
plans to give you hope and a future.” 
Jeremiah 29:11 
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Chapter 1 
 
 
 
SYNTHESIS AND OPTIMIZATION OF A MODEL SYSTEM 
REPRESENTING THE NATURAL PRODUCT MARINEOSIN A  
 
 
 
1.1. Introduction 
 
 In 2008, Fenical and co-workers isolated marineosin A along with a less abundant 
isomer, marineosin B, from a marine sediment-derived actinomycete.1 Although both 
compounds exhibited cytotoxicity, marineosin A proved more potent.  The intriguing 
biological activity and novel chemical structure warranted completion of the total 
synthesis of this compound, which remains a challenging goal.  The initial proposed 
biosynthesis failed in the laboratory, and, despite significant interest from the synthetic 
community, limited syntheses en route to marineosin A have been reported.2–4 The 
following describes the successful synthesis of model systems, designed to be a portion 
of the natural products.  They were created as tools to develop chemistry and test the 
viability of proposed synthetic routes toward marineosin A.  Moreover, the model 
systems were designed as possible minimal pharmacophores, which would greatly 
simplify structure-activity relationship (SAR) studies around the biologically active 
natural products.   
 
1.1.1. Marineosins A and B  
 
 In 2008, Fenical and co-workers described the isolation, structural determination, 
and biological evaluation of two novel spiroiminal alkaloids, marineosins A and B (1.1 
and 1.2, Figure 1.1).1 The marineosins were isolated off the shore of La Jolla, California, 
	   2	  
from marine-derived actinomycete strain CNQ-617 (identified by 16S rDNA sequence 
data analysis).1 Many actinomycetes are harmless, some are pathogens, and others have 
become an important source for secondary metabolites, including sources of antibiotics.  
Interestingly, the marineosins are thought to be a new species in the genus Streptomyces, 
which has been shown to have adapted to marine life and has produced a number of 
antibiotics.1  
 
 
Figure 1.1.  Structures of marineosins A (1.1) and B (1.2). 
 
 
 
 The natural products were analyzed by optical rotation, UV spectroscopy, high- 
and low-resolution ESI, HRFABMS, IR spectroscopy, 1H and 13C NMR spectroscopy 
(including DEPT), and 2D NMR spectroscopy (including COSY, NOESY, HMBC, 
TOCSY, and HSQC-TOCSY).1 1.1 and 1.2 proved to be intriguing synthetic targets 
containing a novel spiroiminal center, two pyrrole moieties, and a 12-membered 
macrocyclic ring.  The compounds are diastereomers with an epimeric relationship 
assigned at the C8 spiroiminal and adjacent C7 stereocenter.  Of note, NOESY 
correlations and 1H NMR vicinal coupling constants indicated that the tetrahydropyran 
(THP) ring in marineosin A (1.1) is in the chair conformation (Figure 1.2) while similar 
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analysis of marineosin B (1.2) confirmed this compound to be in a boat or twist boat 
conformation.  This phenomenon is most likely due to the stabilizing anomeric effect 
expected in 1.1 that may not be present in 1.2 because of the inverted aminal nitrogen.1 
 
 
Figure 1.2. Large-ring conformation of 1.1 suggested by the pyrrole-ring shielded proton 
chemical shifts of H17 and H19.1 (Adapted from Fenical 2008). 
 
 
 Antifungal activities against Candida albicans were extremely weak, but both 1.1 
and 1.2 inhibited the human colon carcinoma HCT-116 cell line at IC50’s of 0.5 µM and 
46 µM, respectively.  Marineosin A (1.1), the major isolated isomer, also proved to be 
broadly cytotoxic with considerable selectivity against melanoma and leukemia cell lines 
in the National Cancer Institute (NCI) 60 cell line panel.1 
 The macrocycle of the marineosins resembles the cycloalkyl side chains of the 
prodigiosin alkaloids, secondary metabolites known for their bright red pigments and vast 
range of biological activities.  The tricyclic core is also reminiscent of the bacterial 
prodigiosins.5 These structural similarities indicate that the marineosins could be derived 
from a prodigiosin-like biosynthesis pathway.1 
 
1.1.2. Prodigiosin Alkaloids 
 
 The marineosins closely resemble the prodigiosin alkaloids (Figure 1.3), which 
are produced by various marine bacteria.  The prodigiosins exhibit a myriad of biological  
H
N
H
H
H H
H
1719
H
1.1
marineosin A
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Figure 1.3.  The marineosins are reminescent of the prodigiosin alkaloids. 
 
activities including immunosuppression, antimalarial, antimicrobial, and anticancer 
effects with nominal toxicity on normal cells.5 The prodigiosins possess extended 
conjugation through a pyrrolylpyrromethene skeleton, causing a deep red color, with 
either an alkyl chain or macrocyclic ring as the major substituent.   
 Notably, the conformation of the prodigiosin core in solution is strongly 
dependent on the pH of the solvent.  Two stable isomers exist (1.4 and 1.5, Figure 1.4) 
based on the degree of protonation of the basic nitrogen.  This process is due to an E/Z 
isomerization of the exocyclic double bond of the azafulvene and induces intramolecular 
hydrogen bonding at either the B-ring methoxy group or B-ring nitrogen, respectively.5,6 
It is unlikely that both isomers show the same affinity to their still unidentified cellular 
target(s).  Determining the pharmacology of prodigiosin derivatives with a defined 
configuration, i.e., marineosin A (1.1), could, therefore, be a valuable investigation 
towards a biochemical tool.   
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Figure 1.4.  Two stable isomers of prodigiosin alkaloids in solution.6 
 
 Prodigiosin natural products are produced through a number of biosynthetic 
pathways.  A multitude of synthetic endeavors and SAR studies have focused on these 
compounds, and syntheses in the last 50 years have contributed greatly to heterocyclic 
chemistry.6–8 In particular, Boger and co-workers prepared the core of the prodigiosin 
precursor bipyrrole aldehyde 4-methoxy-2,2’-bipyrrole-5-carbaldehyde (MBC) (1.13, 
Scheme 1.1) utilizing an inverse-electron demand Diels-Alder reaction.9,10 1,2,4,5-
tetrazine (1.6) and 1,1-dimethoxy ethane (1.7) were reacted in dioxane to give pyridazine 
1.8 in 94% yield.  The prodigiosin B-ring (1.9) was established by reacting 1.8 with zinc 
dust and acetic acid.  Subsequent hydrolysis, iodine-mediated iodination, and 
hydrogenolysis provided pyrrole 1.10, which was further reacted with 1H-pyrrole-1-
carboxylic acid to give urea 1.11.  Next, oxidative coupling with stoichiometric polymer-
supported palladium acetate provided 1.12.  Finally, hydrolysis and reduction afforded 
MBC (1.13).   
 Thomson and Clift were the first to demonstrate enantioselective syntheses of two 
of the tripyrrole alkaloids, metacycloprodigiosin (1.25, Scheme 1.2) and prodigiosin R1 
(1.26, Scheme 1.3).11 Metacycloprodigiosin was prepared by a regio- and stereoselective 
1,4-conjugate addition of ethylmagnesium bromide (EtMgBr) to enone 1.14.  The enolate 
NH
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Me
N
R2
H NH
R1
N
N
R2O
Me
H
1.4 1.5
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was then trapped with chlorosilane 1.15.  Oxidative bond formation, ring-closing 
metathesis (RCM), hydrogenation, and Paal-Knorr condensation provided chiral 
macrocyclic pyrrole 1.19.  Aldehyde 1.20 was prepared by methyl oxidation with 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), and aldol condensation afforded 
bipyrrole 1.22.  Triflation, Suzuki coupling, and tert-butyloxycarbonyl (Boc) 
deprotection yielded metacycloprodigiosin (1.25) in 13% overall yield.  This same 
strategy was used to synthesize prodigiosin R1 (1.26) in 7% overall yield.   
 While most SAR studies have focused on derivations of the C-ring,12,13 D’Alessio 
et al. found a nitrogen-containing A-ring and a B-ring alkoxy group to be important for 
immunosuppressive and cytotoxic activity, properties most likely due to different 
mechanisms of action.5,14 Furthermore, Melvin and co-workers found that A-ring 
replacements with substituted indoles and unnatural alkyl pyrrole substituents exhibited 
antiproliferative effects and suggest that the prodigiosins could be used as monotherapy 
or synergistically in combination with existing drugs.15 Obatoclax (GX15-070) (1.27, 
Figure 1.5), a Bcl-2 inhibitor, is an example of a prodigiosin analog currently in phase II 
clinical trials for the treatment of cancer.16,17 
 The tambjamine alkaloids (Figure 1.6) are the most closely related group of 
natural products to the prodigiosins. They differ structurally by an enamine moiety but 
exhibit cytotoxic activity similar to that of the prodigiosins.5 
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Scheme 1.1. Broger and co-workers synthesis of MBC (1.13).9,10  
(Adapted from Boger 1988, 1987). 
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Scheme 1.2. Enantioselective synthesis of metacycloprodigiosin (1.25).11 
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Scheme 1.3. Enantioselective synthesis of prodigiosin R1 (1.26).11 
 
 
Figure 1.5.  Structure of obatoclax (GX15-070) (1.27). 
 
 
Figure 1.6.  General structure of the tambjamine alkaloids. 
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1.2. Significance 
 
 Cancer is a heterogenous disease that can rapidly mutate and become resistant to 
therapy; therefore, cancer drug discovery is difficult and complex. The development of 
probe molecules that can be used to validate “druggable” cancer targets is a critical part 
of the cancer drug discovery process.  
 Although many large pharmaceutical companies have marginalized natural 
product divisions in the last 20–30 years, the increasing failure rate of the modern drug 
discovery process, namely high-throughput screens (HTSs) of synthetic libraries, 
continues to advocate for a role for natural products.18 Historically, drugs were often 
derived from natural products, and they are once again gaining substantial attention, 
especially in the area of oncology. According to the NCI, over half of the drugs approved 
to treat cancer come from a natural product or natural product precursor, and two recently 
approved drugs, eribulin and trabectedin, have come from marine organisms.19  
 Marineosin A (1.1), a marine derived natural product, is biologically interesting in 
that it was shown to inhibit the growth of HCT-116 cells at an IC50 of 0.5 µM.  This 
compound also exhibited broad cytotoxicity with considerable selectivity against 
melanoma and leukemia cell lines.  Therefore, this natural product could serve as a lead 
structure in the search for new tool compounds and/or drugs.1  
 
 
1.2.1.  Towards the Total Synthesis of Marineosin A 
 
 Due to the unprecedented spiroiminal core, these new members of the prodiginine 
family of natural products are also intriguing synthetic targets.  Our synthetic endeavor 
towards 1.1 is a proposed sequence of 29 reactions that begins from a chiral pool starting 
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material and calls for late-stage pyrrole installation. Progress towards the natural product 
has resulted in an advanced synthetic intermediate containing the 12-membered 
macrocyclic pyrrole core.3 The proposed route for the completion of 1.1 is based on 
methodology developed en route to a functionalized model system and final reaction 
conditions determined from the smaller model system described herein.3,20  
 
1.2.2. Determining the Minimal Pharmacophore of Marineosin A and Optimizing 
 Structure-Activity Relationships 
 
 While the synthesis of the natural product is complex, a simplified molecule 
maintaining the cytotoxicity seen in the marineosins would greatly enhance throughput in 
the development of SAR and biological assays, studies critical to the development of 1.1 
as a tool compound. The model system provides a means of studying the SAR of 
unnatural analogs to determine the functional groups necessary for activity as well as 
those that are amenable to transformation. Theoretically, derivations of the most potent 
compounds can then be used to develop a functionally selective and cell-permeable 
chemical probe with low nanomolar potency.  
 
 
1.3. Literature Review 
 
 
 
1.3.1. Evaluation of Fenical’s Biosynthetic Proposal 
 
  Fenical proposed a biosynthetic route (Scheme 1.4) to the marineosins from 
undecylprodigiosin that proceeded through an intramolecular inverse-electron demand 
hetero-Diels-Alder, a reaction known to impart stereoselectivity and stereospecificity to 
highly substituted cyclic cores.1,8 Attempts within the Lindsley group to achieve a  
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Scheme 1.4.  Fenical’s proposed biosynthesis of marineosins A (1.1) and B (1.2).1 
(Adapted from Fenical 2008). 
 
 
biomimetic synthesis of the marineosin core based on this hypothetical cycloaddition 
failed despite examining a broad range of reaction conditions.2  
 In 2010, Aldrich et al. reported the evaluation of Fenical’s proposed biosynthesis 
beginning with the condensation of the known primary precursor to the prodigiosin 
alkaloids, MBC (1.13), with a novel 2-keto-undec-3-enylpyrrole (1.29) to give enone 
1.30.2 This enone could hypothetically undergo an intramolecular, inverse-electron 
demand hetero-Diels-Alder cyclization from above or below the enone plane to give the 
THP ring and spiroiminal (1.31) in one step. Subsequent reduction would give 
marineosins A (1.1) and B (1.2).  
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 Compound 1.13 was easily prepared through literature precedents in the syntheses 
of the tambjamines (1.28) and obatoclax (1.27).  Although enone 1.30 (depicted as a 
single isomer for clarity as a Diels-Alder substrate) was produced in sufficient quantities, 
the proposed Diels-Alder reaction was deemed unsuccessful after exploring hundreds of 
reaction conditions (varying solvents, temperatures, microwave conditions, 
photochemical procedures, and Lewis acid catalysts) (Scheme 1.5).  Employing 
molecular modeling, analysis of the 10,000 lowest energy conformers failed to identify a 
favorable Diels-Alder transition state. Due to flexibility of the long alkyl linker, 
intramolecular hydrogen bonds, and the key atoms remaining separated by at least 5 Å, it 
was concluded that 1.30 is energetically unfavorable towards the proposed mechanism. In 
addition, intermolecular Diels-Alder trials were also unsuccessful, proving the C8–C9 
olefin an insufficient dienophile.  This is likely due to the removal of electron density by 
extended conjugation in the poly-pyrrole π-system.  Therefore, a Diels-Alder 
cycloaddition approach is not a viable route to 1.1 and 1.2 in the laboratory.  
 
 
Scheme 1.5. Attempted inverse-electron demand hetero-Diels-Alder reaction  
of 1.30 to afford 1.31.2 
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 While there have been many successful Diels-Alder cycloadditions en route to 
complex natural products, confirmation of the existence of “Diels-Alderases,” enzymes 
that catalyze Diels-Alder reactions in nature, continues to be elusive.21 Even though an 
enzyme that performs this reaction has not been identified, we cannot rule out that nature 
could generate the correct electronics and conformation required to catalyze the reaction.  
An alternative synthetic strategy that does not proceed through a tripyrrole prodigiosin 
alkaloid intermediate is being pursued in the Lindsley lab since validation of the 
biomimetic approach was unsuccessful. 
 
1.3.2. Snider’s Alternative Biosynthetic Proposal and Spiroiminal Synthesis 
 In 2010, Snider and co-workers proposed an alternative biosynthesis to the 
marineosins (Scheme 1.6).22 Snider’s group was skeptical of Fenical’s suggested 
biosynthesis because of the required six-electron oxidation of undecylprodigiosin (1.32) 
to form 1.30 followed by a four-electron reduction of 1.31 to give the marineosins.  They 
instead proposed a single two-electron oxidation of 1.32 by a RedG homolog, RedG 
being an enzyme in the red gene cluster known to catalyze the production of 
prodigiosins.22,23  
 The gene cluster from which the marineosins were isolated, Streptomyces CNQ-
617, was designated a MAR3 clade has been sequenced by Reynolds and Salem.1,24 
Enzymes MarG and MarA were determined to be involved in the biosynthesis of the 
marineosins.  In Snider’s proposal, the RedG homolog oxidizes 1.32 to form either a 
radical or cation, which in turn undergoes an intramolecular Friedel-Crafts reaction to 
form 1.33.  A related enzyme could form radical 1.34 by oxidizing the adjacent carbon.   
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Scheme 1.6. Snider’s alternative biosynthesis of the marineosins.22 
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This radical could then add to the exocyclic olefin to produce macrocyclic radical 1.35, 
which transforms to macrocycle 1.36 with a simple, 1,5-hydride shift.  Because the 
radical in 1.36 is adjacent to the enzyme active site responsible for generating radical 
1.34, this compound could be oxidized to macrocyclic alcohol 1.37, which could then 
proceed through a 1,5-sigmatropic hydride shift to form either 1H-pyrrole 1.38 or 3H-
pyrrole 1.39.  While formation of both 1.38 and 1.39 are theoretically possible, it is 
unlikely that 1.38 would cyclize to form the marineosins due to the required loss of 
pyrrole aromaticity, which would be energetically unfavorable.  More likely, 1.39 would 
rapidly cyclize to form spiroaminal 1.40, and the enamine would tautomerize to the 
imine, giving the natural products.  In this mechanism, only a single enzyme, likely a 
nonheme iron-dependent dioxygenase, would be necessary to convert 1.32 to 1.1 and 1.2.  
Snider and co-workers went on to prepare a model of the spiroiminal moiety (1.43, 
Scheme 1.7) of 1.1 and 1.2 based on this proposal.22  
 
 
 
Scheme 1.7. Snider’s spiroiminal model system.22 (Adapted from Snider 2010).  
 
 
 
 Snider’s approach to model 1.43 included early incorporation of the A-ring pyrrole 
and was based on routes in which the dihydropyrrole ring of the spiroiminal is formed 
before the THP.  They found the A-ring pyrrole to be unstable and subject to methylation 
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and initially developed a route to phenyl-substituted spiroiminals from enone 1.44 
(Scheme 1.8). Ultimately, their final model synthesis required protection of the pyrrole 
substituent.   
 
 
 
Scheme 1.8. Snider’s synthesis of the spiroiminal core of marineosins A (1.1) and B 
(1.2).22 (Adapted from Snider 2010). 
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  Beginning with lactone 1.41, they prepared a model of the marineosins lacking only 
the macrocyclic ring.  Vinylmagnesium bromide opened the lactone to the known 
hydroxyl ketone (85% yield), which was quenched with triethylsilyl chloride (TES-Cl) to 
form enone 1.44 in 96% yield. This enone was then reacted with oxime 1.45 in aqueous 
sodium hypochlorite to provide isoxazoline 1.42.  Hydrogenolysis of isoxazoline 1.42 
with Raney nickel followed by methylation with iodomethane (MeI) gave iminal 1.46. 
Exposure of iminal 1.46 to hydrochloric acid (HCl) provided various amounts of all of 
the possible marineosin diastereomers.  Removal of the TES protecting groups from the 
diastereomers provided the deprotected analogs (1.51–1.53), which were obtained after 
14–20 days of equilibration.22 
 The seven-step route, which included long equilibration times and inseparable 
equilibration mixtures, led to spiroiminals with the same relative stereochemistry as the 
marineosins.  Comparison of these models, which contain an equatorial methyl group, 
with the marineosins suggests that the trans-fused macrocyclic ring in the natural 
products forces the methyl group into an axial conformation.  Snider comments that steric 
interactions between the methoxy group and the A-ring pyrrole largely prevent the 
formation of the other two, less stable, isomers at the spiroiminal center (C8).22 
 
1.3.3.  Snider’s Functionalized Model System and Progress Towards Marineosin A 
 Earlier this year, Snider’s group published a more functionalized model system in 
order to obtain a spiroiminal with the correct conformation as 1.1.25 The 11-step synthesis 
installs a C9 phenyl and a C21 propyl group into their previous model system, forcing the 
pyran into the marineosin A conformation (1.56, Scheme 1.9).  In the same paper, they 
	   19	  
describe a 10–step stereospecific synthesis of macrocyclic pyrrole lactone 1.59 followed 
by a 5–step transformation to a hemi-iminal intermediate (1.60, Scheme 1.10).  This 
intermediate proved to be extremely acid sensitive and decomposed upon both 
methylation and spiroiminal formation, steps necessary to form 1.1. TES protection of 
macrocyclic pyrrole 1.59 failed to form the hemi-iminal, and deprotection of this 
compound also proved unsuccessful.25   
 
 
Scheme 1.9. Snider’s functionalized model system 1.56.25 (Adapted from Snider 2013). 
 
 
Scheme 1.10. Snider’s attempted synthesis of marineosin A (1.1).25 
(Adapted from Snider 2013). 
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1.4. Synthesis and Optimization of Model System 
 
 Snider’s model system proved to be a significant development towards the 
synthesis of the marineosins; however, our group envisioned a synthesis avoiding early 
pyrrole installation.22 Previous synthesis attempts within the Lindsley group had, like 
Snider, found the A-ring pyrrole to be unstable and prone to reactivity issues, leaving 
advanced intermediates and strategies ultimately abandoned.  Therefore, a route avoiding 
early pyrrole incorporation could prove valuable towards the total synthesis of 1.1 and 
1.2.  We developed a six step enantioselective route to two spiroiminal model systems 
reminiscent of 1.1 and 1.2 with late stage pyrrole installment via nucleophilic 
displacement of an iminium triflate salt.20 
 The maleimide-based methodology is based on Huang and co-workers concise 
and selective synthesis of aza-spiropyran 1.64 (Scheme 1.11) in which Grignard addition 
to a chiral hydroxy-maleimide followed by acid-catalyzed intramolecular N-acyliminium 
cyclization forms the spiroaminal core.26 We prepared maleimide 1.67 (Scheme 1.12) 
from a known procedure, refluxing (R)-hydroxysuccinic acid (1.65) with p-
methoxybenzyl amine (1.66) in m-xylene for 24 hours.27 Purification by recrystallization 
from benzene provided 1.67 in 78% yield.  The free hydroxyl group was subsequently 
alkylated with MeI and silver(I) oxide in acetonitrile at reflux for one hour.  Purification 
by flash chromatography provided 1.68 (78% yield), the relevant maleimide for a model 
system of 1.1. 
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Scheme 1.11. Huang’s stereoselective synthesis of aza-spiropyran 1.64.26 
 
 
  
 
Scheme 1.12. Synthesis of key maleimide 1.68.20 
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Scheme 1.13. Synthesis of key Grignard reagent 1.73.20 
 
 With the two key fragments, 1.68 and 1.73, in hand, we were equipped to form 
the spiroaminal (Scheme 1.14).  The solution of Grignard 1.73 was added dropwise to 
ether 1.68 in THF at -20 °C.  This reaction mixture was kept between -10 and  -15 °C and 
was quenched with water after 2.5 hours.  Purification by flash chromatography afforded 
tertiary alcohol 1.74 as an epimeric mixture in a combined yield of 80%.  Addition of p-
TsOH cleaved the THP ether to form iminium salt 1.75, which was cyclized to form 
spiroaminal 1.76 (80% yield) as a single diasteromer, a conversion directed by the C7 (R)-
methoxy substituent.  Removal of the para-methoxybenzyl (PMB) protecting group by 
ceric ammonium nitrate (CAN) generated lactam 1.77 in 67% yield.20    
 The stereochemistry of 1.76, with anti O7, O8 geometry, was determined by 
NOESY and literature precedents (Figure 1.7).29 While the stereochemistry of the model 
system at C7 is the same as 1.1, the absolute stereochemistry at C8 is opposite that of the 
natural product.  Compound 1.76, however, still proved useful as a tool to study 
conditions for final A-ring pyrrole installation.   
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Scheme 1.14. Synthesis of spiroaminal moiety of marineosin A (1.1).20  
 
  
Figure 1.7. Diagnostic nOe correlations in spiroaminal 1.76.20 
 
 
 We planned to install the pyrrole through classical Vilsmeier-type chemistry using 
phosphorus oxychloride (POCl3) and pyrrole, but these attempts proved unsuccessful.29 
Transforming the lactam to the triflate followed by a Suzuki coupling with N-protected, 
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Scheme 1.15. Attempts to install the A-ring pyrrole moiety.20 
 
 In 2000, Baraznenok et al. had shown that addition of triflic anhydride to indolin-2-
one followed immediately by the addition of a functionalized indole afforded the bis-
indole product.30 Based on this precedent, we treated lactam 1.77 with 2.0 equivalents of 
triflic anhydride (Tf2O) to generate the iminium triflate salt.  Addition of 5.0 equivalents 
of pyrrole in dichloromethane at 0 °C provided only a trace amount (<5% yield) of model 
system 1.78.  After assessment of the reaction conditions, we found that using only 1.0 
equivalent of triflic anhydride provided the desired model system (1.78) of 1.1 in 36% 
yield (~9% yield overall) (Scheme 1.16).  A two-dimensional NOESY experiment 
confirmed the stereochemistry of 1.78 (Figure 1.8).  We did not see any equilibration to 
the syn O7, O8 isomer even after two weeks in deuterated chloroform.22,29 This lack of 
epimerization is likely due to favorable stabilization of the oxocarbenium ion and lack of 
a disruptive diaxial interaction.   
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Scheme 1.16. Late stage installation of the A-ring pyrrole.20 
 
 
Figure 1.8. Diagnostic nOe correlations in model system 1.78 reminiscent of  
marineosin A (1.1).20  
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pyran ring will provide the syn isomers based on increased steric demands.20 
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Scheme 1.17. Synthesis of model system 1.87 reminiscent of marineosin B (1.2). (a) 
Preparation of (S)-maleimide fragment (1.83).  (b) Preparation of (S)-spiroiminal (1.87). 
 
 
 
for biological activity.20 These compounds also proved to be inactive in a large kinase 
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Scheme 1.18. Optimization of late-stage pyrrole installation. 
 
 
1.5. Conclusions  
 
 In conclusion, we have developed an enantioselective synthesis of two 
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Scheme 1.19. Envisioned completion of marineosin A (1.1) based on developed model 
system 1.78.20 (Adapted from Lindsley 2013).   
 
 
 
the natural product include a carbon-carbon bond forming Stetter reaction, a macrocyclic 
ring closing metathesis, and a Paal-Knorr pyrrole synthesis, which provides the most 
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hydrochloric acid (HCl) provided spiroaminal 1.113, which was confirmed to have the 
same absolute stereochemistry as marineosin A (1.1) (Figure 1.9).3 At this point in the 
synthesis, treatment with phosphorous oxychloride and pyrrole were used to provide the 
spiroiminal A-ring pyrrole.29   While there was formation of the desired product, the  
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Scheme 1.20. Route to macrocyclic pyrrole 1.109 via critical intermediate 1.102.3 
(Adapted from Lindsley 2013).  
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Scheme 1.21. Synthesis of the spiroaminal lactam moiety of marineosin A (1.1).3  
 
 
 
Figure 1.9. Diagnostic correlations in model system 1.113.3 
 
 
 
considerable polarity did not allow for separation from the pyrrole solvent and the 
instability did not allow for reverse-phase chromatography, thus indicating the need for 
different reaction conditions.8   
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stability of this compound is unknown, degradation ensued after four days on the bench, 
where it was exposed to air and light. Storing this compound at 0 °C under argon may 
prevent degradation from occurring.  However, pyrrole protection may be necessary to 
progress the substrate through successive reactions.  
 Successful completion of the total synthesis of these complex compounds remains 
a challenging goal.  However, once the synthesis of the more potent marineosin A (1.1) is 
accomplished, a thorough biological screening will be completed.  Furthermore, in order 
for 1.1 and/or its derivatives to be useful tool compounds, the target(s) of these 
compounds must also be elucidated.  Therefore, this work has the potential to elucidate a 
new target for cancer drug design. In the event that the marineosin A (1.1) target is not a 
new target, useful correlations made between these molecules and current cancer research 
will still be obtained.  Additionally, completion of this research will add to the current 
knowledge of the prodigiosins and has the potential to produce compounds that are 
antimalarial, immunosuppressive, and/or antibacterial, as have been found with the 
prodigiosin compounds.   
 
1.7. Experimental Section 
 
 
 
1.7.1.  Methods and Materials 
 
    All reagents and solvents were commercial grade and purified prior to use when 
necessary. Analytical TLC was performed on Sorbent Technologies HL 0.25 mm silica 
gel plates with UV indicator. Visualization was accomplished by irradiation under a 254 
nm UV lamp and/or the use of an iodine chamber. Chromatography on silica gel was 
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performed using Silica Gel 60 (230-400 mesh) from Sorbent Technologies. 
   1H and 13C NMR spectra were recorded on a Bruker DRX-400 (400 and 100 MHz, 
respectively) NMR instrument. Chemical shifts are reported in ppm from the solvent 
resonance as an internal standard. Data are reported as follows: chemical shift, 
multiplicity, coupling constant (Hz), and number of protons. 
    Optical rotations were measured on a JASCO P-2000 digital polarimeter at room 
temperature. Concentration (c) in g/100 mL and solvent are given in parentheses. 
 A Micromass Q-Tof API-US mass spectrometer was used to acquire HRMS data. 
The value ∆ is the error in the measurement (in ppm) given by the equation ∆ = [(ME – 
MT)/ MT] × 106, where ME is the experimental mass and MT is the theoretical mass. The 
HRMS results were obtained with ES as the ion source and leucine enkephalin as the 
reference. 
 
 
1.7.2. Experimental Procedures 
 
 
 
 
(R)-3-hydroxy-1-(4-methoxybenzyl)pyrrolidine-2,5-dione (1.67). To a solution of (R)-
2- hydroxysuccinic acid (3.2 g, 24.0 mmol) in 50% aqueous methanol (5 mL) was slowly 
added (4-methoxyphenyl)methanamine (3.14 mL, 24.0 mmol). Methanol was removed 
under reduced pressure. The reaction mixture was partitioned with m-xylene (64 mL) and 
heated to 190 °C. Water was azeotropically removed with a Dean-Stark trap. After 24 
N
PMB
O O
HO
1.67
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hours, the solvent was removed under reduced pressure. The residue was partitioned with 
ethanol (25 mL) and concentrated. Recrystallization from benzene provided 4.4 g (78%) 
of maleimide 1.67. 1H NMR (CDCl3, 400 MHz) δ 2.66 (dd, J = 4.8, 18.2 Hz, 1H), 2.93 
(bs, 1H), 3.05 (dd, J = 8.5, 18.2 Hz, 1H), 3.78 (s, 3H), 4.56-4.65 (m, 3H), 6.83 (d, J = 8.7 
Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H). 13C NMR (CDCl3, 100 MHz) δ 37.1, 41.8, 55.2, 66.8, 
113.9, 127.4, 130.3, 159.3, 174.0, 178.3. HRMS (TOF, ES+): C12H13NO4Na [M+Na]+ 
calcd 258.0742, found 258.0741. [α]22D = + 43.1 (c 1, MeOH). 
 
 
(R)-3-methoxy-1-(4-methoxybenzyl)pyrrolidine-2,5-dione (1.68). To a solution of 
maleimide 1.67 (4.15 g, 20.3 mmol) in acetonitrile (40 mL) at rt was added silver(I) 
oxide (4.69 g, 20.3 mmol) and MeI (3.6 mL, 57.9 mmol). The reaction mixture was 
refluxed for 1 h. After cooling to rt the reaction mixture was filtered and concentrated. 
The residue was purified on silica gel (20:80 EtOAc:hexanes) to provide 3.92 g (78%) of 
ether 1.68. 1H NMR (CDCl3, 400 MHz) δ 2.60 (dd, J = 4.2, 18.2 Hz, 1H), 2.98 (dd, J = 
8.2, 18.2 Hz, 1H), 3.60 (s, 3H), 3.78 (s, 3H), 4.18 (dd, J = 4.2, 8.2 Hz, 1H), 4.59 (d, J = 
2.4 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H). 13C NMR (CDCl3, 100 
MHz) δ 35.5, 41.3, 54.9, 58.4, 74.5, 113.7, 127.5, 123.0, 159.0, 173.6, 175.1. HRMS 
(TOF, ES+): C13H15NO4Na [M+Na]+ calcd 272.0899, found 272.0900. [α]22D = +45.7 (c 
1, MeOH). 
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4-bromobutan-1-ol (1.70). To neat, refluxing THF (67.5 mL, 832 mmol) was added 
48% aqueous hydrobromic acid (31 mL, 274 mmol) dropwise. The reaction mixture was 
held at reflux for 2 hours. After cooling to rt, the reaction was neutralized with saturated 
NaHCO3, extracted with diethyl ether, dried over sodium sulfate, and concentrated to 
provide 31.4 g (75%) of alcohol 1.70. NMR spectra matched that of commercial-grade 
material. 
 
 
 
2-(4-bromobutoxy)tetrahydro-2H-pyran (1.72). To a stirred solution of alcohol 1.70 
(1.95 g, 12.7 mmol) in diethyl ether (12 mL) at 0 °C was added p-TsOH (5 mg, 0.02 
mmol) followed by dropwise addition of 3,4-dihydro-2H-pyran (1.5 mL, 16.6 mmol). 
The reaction mixture was allowed to reach rt. After 1 h, the reaction mixture was washed 
with saturated NaHCO3 (2 x 10 mL) and brine. The organic layer was dried over K2CO3, 
filtered, and concentrated to provide 2.70 g (90%) of pyran 1.72. NMR spectra matched 
that of a literature report.28  
 
 
Br
OH
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(4R)-5-hydroxy-4-methoxy-1-(4-methoxybenzyl)-5-(4-((tetrahydro-2H-pyran-2- 
yl)oxy)butyl)pyrrolidin-2-one (1.74). A flame-dried flask was charged with magnesium 
powder (447 mg, 18.4 mmol) and placed under an inert argon atmosphere. The 
magnesium was suspended in anhydrous THF (21 mL). To this mixture was added pyran 
1.72 (1.4 mL, 7.5 mmol). After warming to 50 °C, pyran 1.72 (2.0 mL, 10.7 mmol) was 
added dropwise. The reaction mixture was heated periodically until it sustained reflux. A 
separate flame-dried flask was charged with ether 1.68 (1.5 g, 6.0 mmol) and THF (30 
mL). After cooling to −20 °C, the solution of Grignard 1.73 was added dropwise via 
syringe. The reaction mixture was kept between −10 °C and −15 °C. After 2.5 h, water (5 
mL) was added and the reaction was allowed to reach rt. The product was extracted with 
diethyl ether (3 x 20 mL). The combined organics were washed with brine, dried over 
Na2SO4, and concentrated. The residue was purified on silica gel (30:70 EtOAc:hexanes) 
to provide 6.61 g (80%) of tertiary alcohol 1.74. 1H NMR (CDCl3, 400 MHz) δ 1.48-1.59 
(m, 5H), 1.61-1.75 (m, 2H), 1.77-1.90 (m, 1H), 2.12-2.24 (m, 2H), 2.57 (d, J = 17.9 Hz, 
1H), 2.71 (dddd, J = 1.9, 7.2, 17.8 Hz, 1H), 3.27 (s, 3H), 3.29-3.34 (m, 1H), 3.45-3.50 
(m, 1H), 3.63-3.71 (m, 1H), 3.77 (s, 3H), 3.80-3.85 (m, 1H), 4.49-4.52 (m, 1H), 4.55- 
4.66 (m, 3H), 4.85 (q, J = 6.8 Hz, 1H), 6.81 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 8.6 Hz, 2H). 
13C NMR (CDCl3, 100 MHz) δ 19.6, 19.8, 23.4, 23.5, 25.4 (2C), 30.1, 30.2, 30.7, 30.8, 
36.0 (2C), 42.9 (2C), 55.1, 55.2, 62.3, 62.6, 66.5, 66.7, 72.0 (2C), 98.9, 99.0, 107.0, 
107.1, 113.9 (2C), 127.9, 128.3, 128.4, 139.2, 139.3, 158.8 (2C), 173.0, 173.1. HRMS 
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(TOF ES+): C22H33NO6Na [M+Na]+ calcd 430.2206, found 430.2210. [α]22D = −15.0 (c 
0.6, CHCl3). HRMS (TOF, ES+): C13H15NO4Na [M+Na]+ calcd 272.0899, found 
272.0900. 
 
 
(4R,5S)-4-methoxy-1-(4-methoxybenzyl)-6-oxa-1-azaspiro[4.5]decan-2-one (1.76). To 
a stirred solution of tertiary alcohol 1.74 (390 mg, 1.0 mmol) in CH2Cl2 (6 mL) at 0 °C 
was added p-TsOH monohydrate (41 mg, 0.2 mmol). After 30 minutes the solvent was 
removed. The residue was purified on silica gel (30:70 EtOAc:hexanes) to provide 244 
mg (80%) of spiroaminal 1.76. 1H NMR (CDCl3, 400 MHz) δ 1.39-1.51 (m, 4H), 1.63-
1.70 (m, 1H), 1.85-1.92 (m, 1H), 2.47 (d, J = 17.4 Hz, 1H), 2.65 (dd, J = 5.5, 17.4 Hz, 
1H), 3.32 (s, 3H), 3.61 (m, 1H), 3.73 (s, 3H), 3.84 (dd, J = 2.4, 11.2 Hz, 1H), 3.95 (d, J = 
5.5 Hz, 1H), 4.11 (d, J = 16.0 Hz, 1H), 4.70 (d, J = 16.0 Hz, 1H), 6.78 (d, J = 8.7 Hz, 
2H), 7.14 (d, J = 8.7 Hz, 2H). 13C NMR (CDCl3, 100 MHz) δ 20.0, 24.6, 27.9, 34.3, 41.8, 
55.0, 56.6, 64.7, 74.9, 94.9, 113.5, 127.9, 130.5, 158.2, 174.5. HRMS (TOF, ES+): 
C17H24NO4 [M+H]+ calcd 306.1705, found 306.1702. [α]22D = −50.6 (c 1, CHCl3). 
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(4R,5S)-4-methoxy-6-oxa-1-azaspiro[4.5]decan-2-one (1.77). To a stirred solution of 
spiroaminal 1.76 (258 mg, 0.85 mmol) in acetonitrile (27 mL) and water (3.5 mL) was 
added CAN (1.4 g, 2.5 mmol). After 1.5 h, a second portion of CAN (467 mg, 0.8 mmol) 
was added. After 1 h, the acetonitrile was removed under reduced pressure. The product 
was extracted with CH2Cl2 (4 x 15 mL). The combined organic layers were washed with 
brine, dried over Na2SO4, and concentrated. The residue was purified on silica gel (30:70 
EtOAc/hexanes) to provide 105 mg (67%) of amide 1.77. 1H NMR (CDCl3, 400 MHz) δ 
1.54-1.63 (m, 2H), 1.63-1.73 (m, 1H), 1.73-1.83 (m, 3H), 2.29 (dd, J = 1.7, 17.2 Hz, 1H), 
2.70 (dd, J = 5.6, 17.2 Hz, 1H), 3.34 (s, 3H), 3.66-3.72 (m, 3H), 8.64 (bs, 1H). 13C NMR 
(CDCl3, 100 MHz) δ 19.4, 25.2, 29.3, 35.7, 57.3, 62.7, 82.4, 91.8, 177.3. HRMS (TOF, 
ES+): C9H16NO3 [M+H]+ calcd 186.1130, found 186.1131. [α]22D = −97.1 (c 1.1, CHCl3). 
 
	  
(4R,5S)-4-methoxy-2-(1H-pyrrol-2-yl)-6-oxa-1-azaspiro[4.5]dec-1-ene (1.78). A 
flame- dried flask was charged with amide 1.77 (64 mg, 0.3 mmol) and placed under an 
inert argon atmosphere. After cooling to 0° C, CH2Cl2 (4 mL) and 
trifluoromethanesulfonic anhydride (58.2 µL, 0.3 mmol) were added. After 2 minutes, 
pyrrole (119.8 µL, 1.7 mmol) was added. After 10 minutes, the reaction was quenched 
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with saturated NaHCO3 and allowed to reach rt. The product was extracted with CH2Cl2 
(3 x 5 mL). The combined organics were dried over Na2SO4 and concentrated. The 
residue was purified on silica gel (30:70 EtOAc/hexanes) to provide 29 mg (36%) of 
pyrrole 1.78. 1H NMR (CDCl3, 400 MHz) δ 1.54-1.78 (m, 5H), 1.86-1.99 (m, 2H), 2.78 
(dd, J = 5.3, 16.5 Hz, 1H), 3.21 (dd, J = 6.8, 16.5 Hz, 1H), 3.44 (s, 3H), 3.72 (d, J = 10.8 
Hz, 1H), 3.84 (t, J = 6.2 Hz, 1H), 4.15 (dt, J = 2.8, 11.1 Hz, 1H), 6.21 (t, J = 3.2 Hz, 1H), 
6.57 (d, J = 3.5 Hz, 1H), 6.90 (s, 1H). 13C NMR (CDCl3, 100 MHz) δ 19.6, 25.8, 29.2, 
38.7, 58.2, 64.2, 85.3, 102.8, 110.7, 112.8, 121.1, 126.3, 164.6. HRMS (TOF, ES+): 
C13H19N2O2 [M+H]+ calcd 235.1447, found 235.1447. [α]22D = −65.2 (c 1.6, CHCl3). 
 
 
(S)-3-hydroxy-1-(4-methoxybenzyl)pyrrolidine-2,5-dione (1.82). To a solution of (S)- 
2-hydroxysuccinic acid (8.05 g, 60.0 mmol) in 50% aqueous methanol (12 mL) was 
slowly added (4-methoxyphenyl)methanamine (7.84 mL, 60.0 mmol). Methanol was 
removed under reduced pressure. The reaction mixture was partitioned with m-xylene 
(160 mL) and heated to 190 °C. Water was azeotropically removed with a Dean-Stark 
trap. After 24 hours, the solvent was removed under reduced pressure. The residue was 
partitioned with ethanol (50 mL) and concentrated. Recrystallization from benzene 
provided 10.99 g (78%) of maleimide 1.82. 1H NMR (CDCl3, 400 MHz) δ 2.66 (dd, J = 
4.8, 18.2 Hz, 1H), 2.93 (bs, 1H), 3.05 (dd, J = 8.5, 18.2 Hz, 1H), 3.78 (s, 3H), 4.56-4.65 
(m, 3H), 6.83 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H). 13C NMR (CDCl3, 100 MHz) 
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δ 37.1, 41.8, 55.2, 66.8, 113.9, 127.4, 130.3, 159.3, 174.0, 178.3. HRMS (TOF, ES+): 
C12H13NO4Na [M+Na]+ calcd 258.0742, found 258.0741. [α]22D = 44.5 (c 1, MeOH). 
 
 
(S)-3-methoxy-1-(4-methoxybenzyl)pyrrolidine-2,5-dione (1.83). To a solution of 
maleimide 1.82 (8.00 g, 34.0 mmol) in acetonitrile (70 mL) at rt was added silver(I) 
oxide (7.88 g, 34.0 mmol) and iodomethane (6.1 mL, 97.2 mmol). The reaction mixture 
was refluxed for 1 h. After cooling to rt the reaction mixture was filtered and 
concentrated. The residue was purified on silica gel (20:80 EtOAc:hexanes) to provide 
6.61 g (78%) of ether 1.83. 1H NMR (CDCl3, 400 MHz) δ 2.60 (dd, J = 4.2, 18.2 Hz, 
1H), 2.98 (dd, J = 8.2, 18.2 Hz, 1H), 3.60 (s, 3H), 3.78 (s, 3H), 4.18 (dd, J = 4.2, 8.2 Hz, 
1H), 4.59 (d, J = 2.4 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H). 13C 
NMR (CDCl3, 100 MHz) δ 35.5, 41.3, 54.9, 58.4, 74.5, 113.7, 127.5, 123.0, 159.0, 173.6, 
175.1. HRMS (TOF, ES+): C13H15NO4Na [M+Na]+ calcd 272.0899, found 272.0900. 
[α]22D = −55.6 (c 1, MeOH). 
 
 
(4S)-5-hydroxy-4-methoxy-1-(4-methoxybenzyl)-5-(4-((tetrahydro-2H-pyran-2- 
yl)oxy)butyl)pyrrolidin-2-one (1.84). A flame-dried flask was charged with magnesium 
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powder (1.51 g, 60.8 mmol) and placed under an inert argon atmosphere. The magnesium 
was suspended in anhydrous THF (70 mL). To this mixture was added pyran 1.72 (3.8 
mL, 20.3 mmol). After warming to 50 °C, pyran 1.72 (7.6 mL, 40.5 mmol) was added 
dropwise. The reaction mixture was heated periodically until it sustained reflux. A 
separate flame- dried flask was charged with ether 1.83 (5.05 g, 20.3 mmol) and THF 
(100 mL). After cooling to −20 °C, the solution of Grignard 1.73 was added dropwise via 
syringe. The reaction mixture was kept between −10 °C and −15 °C. After 2.5 h, water 
(10 mL) was added and the reaction was allowed to reach rt. The product was extracted 
with diethyl ether (3 x 20 mL). The combined organics were washed with brine, dried 
over Na2SO4, and concentrated. Tertiary alcohol 1.84 was used in the next reaction 
without any further purification. 
 
	  
(4S,5R)-4-methoxy-1-(4-methoxybenzyl)-6-oxa-1-azaspiro[4.5]decan-2-one (1.85). To 
a stirred solution of tertiary alcohol 1.84 (6.82 g, 16.8 mmol) in CH2Cl2 (100 mL) at 0 °C 
was added p-TsOH monohydrate (796 mg, 4.19 mmol). After 30 minutes the solvent was 
removed. The residue was purified on silica gel (30:70 EtOAc:hexanes) to provide 4.28 g 
(84%) of spiroaminal 1.85. 1H NMR (CDCl3, 400 MHz) δ 1.39-1.51 (m, 4H), 1.63-1.70 
(m, 1H), 1.85-1.92 (m, 1H), 2.47 (d, J = 17.4 Hz, 1H), 2.65 (dd, J = 5.5, 17.4 Hz, 1H), 
3.32 (s, 3H), 3.61 (m, 1H), 3.73 (s, 3H), 3.84 (dd, J = 2.4, 11.2 Hz, 1H), 3.95 (d, J = 5.5 
Hz, 1H), 4.11 (d, J = 16.0 Hz, 1H), 4.70 (d, J = 16.0 Hz, 1H), 6.78 (d, J = 8.7 Hz, 2H), 
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7.14 (d, J = 8.7 Hz, 2H). 13C NMR (CDCl3, 100 MHz) δ 20.0, 24.6, 27.9, 34.3, 41.8, 
55.0, 56.6, 64.7, 74.9, 94.9, 113.5, 127.9, 130.5, 158.2, 174.5. HRMS (TOF, ES+): 
C17H24NO4 [M+H]+ calcd 306.1705, found 306.1702. [α]22D = +74.3 (c 1, CHCl3). 
 
 
(4S,5R)-4-methoxy-6-oxa-1-azaspiro[4.5]decan-2-one (1.86). To a stirred solution of 
spiroaminal 1.85 (2.23 g, 7.33 mmol) in acetonitrile (200 mL) and water (30.0 mL) was 
added CAN (12.0 g, 22.0 mmol). After 1.5 h, a second portion of CAN (4.02 g, 7.33 
mmol) was added. After 1 h, the acetonitrile was removed under reduced pressure. The 
product was extracted with CH2Cl2 (4 x 20 mL).  The combined organic layers were 
washed with brine, dried over Na2SO4, and concentrated. The residue was purified on 
silica gel (30:70 EtOAc/hexanes) to provide 911 mg (67%) of amide 1.86. 1H NMR 
(CDCl3, 400 MHz) δ 1.54-1.63 (m, 2H), 1.63-1.73 (m, 1H), 1.73-1.83 (m, 3H), 2.29 (dd, 
J = 1.7, 17.2 Hz, 1H), 2.70 (dd, J = 5.6, 17.2 Hz, 1H), 3.34 (s, 3H), 3.66-3.72 (m, 3H), 
8.64 (bs, 1H). 13C NMR (CDCl3, 100 MHz) δ 19.4, 25.2, 29.3, 35.7, 57.3, 62.7, 82.4, 
91.8, 177.3. HRMS (TOF, ES+): C9H16NO3 [M+H]+ calcd 186.1130, found 186.1131. 
[α]22D = +58.9 (c 1, CHCl3). 
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(4S,5R)-4-methoxy-2-(1H-pyrrol-2-yl)-6-oxa-1-azaspiro[4.5]dec-1-ene (1.87). A 
flame- dried flask was charged with amide 1.86 (18.5 mg, 0.1 mmol) and placed under an 
inert argon atmosphere. After cooling to 0 °C, CH2Cl2 (1 mL) and 
trifluoromethanesulfonic anhydride (17.0 µL, 0.1 mmol) were added. After 2 minutes, 
pyrrole (33.0 µL, 0.5 mmol) was added. After 10 minutes, the reaction was quenched 
with saturated NaHCO3 and allowed to reach rt. The product was extracted with CH2Cl2 
(3 x 5 mL). The combined organics were dried over Na2SO4 and concentrated. The 
residue was purified on silica gel (30:70 EtOAc/hexanes) to provide 8.2 mg (35%) of 
pyrrole 1.87. 1H NMR (CDCl3, 400 MHz) δ 1.54-1.78 (m, 5H), 1.86-1.99 (m, 2H), 2.78 
(dd, J = 5.3, 16.5 Hz, 1H), 3.21 (dd, J = 6.8, 16.5 Hz, 1H), 3.44 (s, 3H), 3.72 (d, J = 10.8 
Hz, 1H), 3.84 (t, J = 6.2 Hz, 1H), 4.15 (dt, J = 2.8, 11.1 Hz, 1H), 6.21 (t, J = 3.2 Hz, 1H), 
6.57 (d, J = 3.5 Hz, 1H), 6.90 (s, 1H). 13C NMR (CDCl3, 100 MHz) δ 19.6, 25.8, 29.2, 
38.7, 58.2, 64.2, 85.3, 102.8, 110.7, 112.8, 121.1, 126.3, 164.6. HRMS (TOF, ES+): 
C13H19N2O2 [M+H]+ calcd 235.1447, found 235.1447. [α]22D = +43.1 (c 1.7, CHCl3). 
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Chapter 2 
 
 
 
DISCOVERY OF VU0431316, A NEGATIVE ALLOSTERIC 
MODULATOR OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 
 
 
 
2.1. Introduction 
 
 Metabotropic glutamate receptor 5 (mGluR5) is involved in a variety of 
psychiatric and neurologic disorders, and mGluR5 therapeutics have the potential to 
dramatically improve the treatments available for these disorders.  Because conventional 
orthosteric modulators of mGluR5 can lack satisfactory aqueous solubility, demonstrate 
poor oral bioavailability, and/or exhibit unfavorable effects, there is a need for selective 
allosteric modulators of mGluR5 that overcome these deficiencies.  While MPEP and 
MTEP have proven to be valuable negative allosteric modulator (NAM) tool compounds, 
both of these compounds have characteristics that prevent them from becoming full 
therapeutic molecules. Thus, there has been an interest in the development of mGluR5 
NAMs within chemotypes that do not contain a disubstituted alkyne motif. The following 
describes the successful discovery of tool compound VU0431316 from an aryl ether 
series of mGluR5 NAMs.   
 
 
2.1.1. Metabotropic Glutamate Receptors  
 
 Metabotropic glutamate receptors (mGluRs) are part of family C (also known as 
family 3) of the G-protein-coupled receptor (GPCR) superfamily.35 GPCRs are 
membrane-bound proteins characterized by seven-transmembrane (7TM) helices that 
transmit extracellular signals through the receptor to internally associated G-proteins.  
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When activated by an extracellular ligand, GPCRs undergo a conformational change that 
activates an associated G-protein, composed of a heterotrimeric complex of α, β, and γ 
subunits.  The activated G-protein exchanges GDP for GTP at the α subunit.  This 
exchange triggers the α subunit as well as the combined β,γ subunit to disassociate from 
the receptor and activate signal transduction pathways (Figure 2.1).35 Not surprisingly, 
GPCRs, the largest class of cell-surface receptors, have been implicated in a number of 
disorders and are the therapeutic target of nearly half of the pharmaceuticals on the 
market today.36 
 GPCRs can be activated by a number of ligands including light, peptides, and 
neurotransmitters (NTs); however, mGluRs are exclusively activated by L-glutamate, the 
most abundant excitatory NT in the mammalian central nervous system (CNS).35,37,38 
Metabotropic glutamate receptors exist as dimers and are distinguished from the other 
families of GPCRs by their large, extracellular domain, known as the Venus flytrap 
domain (VFD) (Figure 2.2).  Extracellular signals are transduced, most likely via a 
disulfide bridge, from the VFD to a cysteine-rich domain (CRD), which connects the 
VFD to the 7TM domain.  Eight subtypes of mGluRs have been identified, many having 
splice variants with differing C-terminal tails.  The eight subtypes are further classified 
into groups (Table 2.1) based on sequence homology, G-protein coupling, and ligand 
selectivity.35   
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Figure 2.1. Diagram of GPCR activation.39 
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Figure 2.2. Monomeric structure of the mGluRs.40 
 
 
Table 2.1. mGluR Group classifications 
 
Group mGluR Subtypes 
I 1, 5 
II 2, 3 
III 4, 6, 7, 8 
 
 
 
 The VFD, located at the N-terminal, contains the glutamate-binding site.  Two 
VFDs are thought to dimerize back to back.  Glutamate binding at one or both of these 
domains causes conformational changes that can activate the receptor, leading to three 
main states of an mGluR: open-open (inactive), closed-open (active), and closed-closed 
(active) (Figure 2.3).  While it remains controversial as to whether or not binding of  
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Figure 2.3. Receptor conformations of the mGluR dimer.35 
 
glutamate to only one dimer actives the entire complex, it is clear that antagonists 
stabilize the open-open (inactive) state.  This indicates that the relative orientation of the 
VFDs is important for activation.   The VFDs also bind the divalent cations magnesium 
and calcium at the orthosteric site, which can also activate or potentiate the receptor.35   
 In general, activating the different groups of mGluRs leads to independent 
intracellular pathways; however, it is now recognized that mGluRs from all groups can 
modulate additional signaling pathways depending on cell type or neuronal population.35 
Group I receptors favor coupling to Gαq, stimulating phospholipase C and increasing 
intracellular calcium and inositol phosphate levels.  These receptors are mostly located 
postsynaptically, and their activation leads to cell depolarization and increasing neuronal 
excitability.  Groups II and III, located presynaptically, predominately couple to Gαi, 
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leading to a decrease in cAMP and typically have an inhibitory effect on NT release at 
various types of synapses.35,38  
 
 
2.1.2. Allosteric Modulators 
 
 The orthosteric binding site is highly conserved across all mGluRs, making it 
difficult to develop selective orthosteric ligands.41 Additionally, many orthosteric ligands, 
designed as glutamate analogs, lack the physical properties required to engender 
favorable drug-like features such as oral bioavailability and/or CNS penetration.38 An 
alternative method of modulating these targets that avoids these issues has been achieved 
through the development of allosteric ligands.  Such allosteric ligands bind at a 
topographically distinct binding site located in the 7TM domain; therefore, these 
compounds are non-competitive with the endogenous glutamate (see Figure 2.2).  The 
higher sequence divergence in the 7TM region across receptor subtypes provides the 
prospect of greater selectivity.  Furthermore, selective cooperativity may favor a certain 
subtype over all others.  Allosteric modulators also have the advantage of providing a 
“ceiling” on the magnitude of their effect, meaning that large doses are less likely than 
their orthosteric counterparts to produce target-based toxic effects.36  
 The allosteric modulator approach has proved effective in many instances, 
garnering much attention from the medicinal chemistry community.38,41 One of the more 
developed areas of allosteric modulation has been the design of small molecule negative 
allosteric modulators (NAMs).41 These compounds do not directly inactivate the 
receptors, but rather decrease the affinity for an orthosteric agonist at the VFD.  Thus, 
NAMs are appropriate agents for inhibiting the physiological activation of mGluRs.38 
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Positive allosteric modulators (PAMs), on the other hand, work to increase the affinity of 
the receptor, potentiating the response to orthosteric agonists.35 Allosteric modulators 
have appropriately been described as dimmer switches that allow receptors to be tuned up 
or down, offering control over the desired intensity of the physiological response.  Figure 
2.4 is a schematic representation of (a) PAM and (b) NAM activity in an in vitro calcium 
mobilization assay.  Increasing PAM concentrations progressively shift the concentration 
response curve (CRC) to the left with increasing potency, while increasing NAM 
concentrations progressively shift the magnitude of glutamate concentration response 
with little change in potency, demonstrating their non-competitive nature.35  
 
 
Figure 2.4. Representative CRCs of increasing PAM and NAM concentrations.35 
 
 
2.2. Significance 
 
  Genetic deletions of the mGluRs in knockout mice have revealed potential roles 
for each of them in cell function in various disease states.35 Specifically, studies of 
synaptic plasticity in the Fmr1 knockout mouse have identified a connection between 
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mGluR5 signaling and fragile-X syndrome (FXS), a leading cause of autism and the most 
common inherited form of mental retardation.  The genetic defect in FXS is in the gene 
encoding the fragile X mental retardation protein, a protein that promotes long-term 
depression (LTD).  Mouse models of FXS show that group I-dependent LTD is 
excessive, suggesting that antagonism of mGluRs 1 or 5 could represent a novel 
mechanism of treatment.35  
 Metabotropic glutamate receptor 5 has also been extensively studied for the 
treatment of anxiety.  The glutamate receptor increases excitability by modulating various 
ion channels and potentiating N-methyl-D-aspartate (NMDA) receptor currents.  
Antagonism could dampen these glutamatergic activities that are thought to underlie 
anxiety disorders.36 In addition, well-studied mGluR5 NAMs indicate that the Group I 
receptor is involved in other disorders such as drug addiction, gastroesophageal reflux 
disease (GERD), and Parkinson’s disease levodopa induced dyskinesia (PD-LID).38 
Overall, because of the ubiquitous distribution of glutamatergic synapses, mGluR 
therapeutics have the potential to dramatically improve the treatments available for a 
wide variety of psychiatric and neurologic disorders.35,42 
 
 
2.3. Literature Review 
 
 In 1999, Varney et al. described the first selective mGluR5 NAMs, SIB-1757 and 
SIB-1893 (2.1 and 2.2, Figure 2.5).43 Allostery proved to be the key to finding highly 
selective inhibitors, exhibiting selectivity not previously seen with any mGluR subtype 
orthosteric ligand.  Subsequent structural analogs led to the development of the 
disubstituted alkynes MPEP and MTEP (2.3 and 2.4, Figure 2.6), the most well studied  
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Figure 2.5. The first selective mGluR5 NAMs, SIB-1757 (2.1) and SIB-1893 (2.2). 
 
 
 
Figure 2.6. mGluR5 tool compounds MPEP (2.3) and MTEP (2.4). 
 
mGluR5 NAMs to date.  Both 2.3 and 2.4 have proven efficacious in numerous animal 
models including those related to drug addiction, anxiety, GERD, FXS, and PD-LID.38,41 
Since the discovery of these tool compounds, many selective mGluR5 NAMs have been 
developed based on the disubstituted alkyne scaffold.  In fact, most of the compounds 
progressing to clinical trials have come from this class of compounds, including three 
with confirmed ongoing clinical activity: RG7090 (RO4917523), mavoglurant 
(AFQ056), and dipraglurant (ADX48621) (2.5, 2.6, and 2.7, Figure 2.7).41 Additionally, 
radioligands and PET tracers for the MPEP allosteric site have been developed to aid in 
the development of clinical compounds.36   
 Clinical validation for mGluR5 NAMs came in 2005 with the development of the 
allosteric antagonist fenobam (2.8, Figure 2.8).  Fenobam was efficacious in a preclinical 
model of anxiety and further demonstrated clinical efficacy as an anxiolytic.36   
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Figure 2.7.  mGluR5 NAMs currently in clinical trials.41 
 
 
 
Figure 2.8. Fenobam (2.8), an anxiolytic mGluR5 allosteric antagonist. 
 
 Potential concerns for the use of mGluR5 NAMs include target-related adverse 
effects such as cognition impairment or psychotomimetic effects.  A possible solution to 
these problems was discovered in 2005 in mGluR5 allosteric partial antagonists.  These 
molecules fully occupy the MPEP site, but, due to limited negative cooperativity, only 
partially block agonist responses resulting in partial inhibition of the receptor.  M-5MPEP 
and Br-5MPEPy (2.9 and 2.10, Figure 2.9) were shown to maximally inhibit mGluR5 by 
50% at full occupation, demonstrating a reduction in response along with some level of 
activity maintenance.36 
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Figure 2.9. M-5PEP (2.9) and Br-5MPEPy (2.10), mGluR5 allosteric partial antagonists. 
 
2.4. Discovery of VU0431316 
  
 While MPEP and MTEP have proven to be valuable tool compounds, both of 
these compounds have characteristics that prevent them from becoming full therapeutic 
molecules.  Namely, MPEP has been shown to directly inhibit NMDA receptor activity at 
high concentrations.  Moreover, it is also considered to be an mGluR4 PAM.   MTEP, on 
the other hand, does not exhibit any selectivity issues but is a potent inhibitor of 
cytochrome P450 A12, which could potentially lead to adverse drug interactions.  MTEP 
is also efficiently cleared when administered intravenously to rhesus monkeys.38 
 Further, because conventional orthosteric modulators of mGluR5 can lack 
satisfactory aqueous solubility, demonstrate poor oral bioavailability, and/or exhibit 
unfavorable effects, there is a need for selective negative allosteric modulators of 
mGluR5 that overcome these deficiencies.38 We, therefore, have been interested in 
developing mGluR5 NAMs within chemotypes that do not contain a disubstituted alkyne 
motif.41 Herein describes the discovery of tool compound VU0431316 (2.11, Figure 2.10) 
from an aryl ether series of mGluR5 NAMs.   
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Figure 2.10. mGluR5 NAM tool compound 2.11 (VU0431316).  
 
 
2.4.1. Development of Structure-Activity Relationships 
  
 We began our search for novel chemotypes of mGluR5 NAMs by developing hits 
identified from a functional cell-based HTS of 160,000 compounds.  This is the same 
assay utilized as our primary assay for lead optimization and works by measuring the 
ability of a compound to block the mobilization of calcium induced by an EC80 
concentration of glutamate in HEK293A cells expressing rat mGluR5.  Aryl ether 
benzamide 2.12 was among the confirmed hits demonstrating good potency and was 
subjected to initial structural modifications (Figure 2.11).41 Removal of the primary 
amine provided 2.13, which proved to be four-fold more potent than 2.12.  Alternating 
the orientation of the amide bond afforded compound 2.14.  While 2.14 was more than 
20-fold less potent than 2.13, it was ultimately optimized to tool compound VU0409106 
as recently described by Felts et al. (2.15, Figure 2.12).41 We envisioned that further 
optimization of 2.13 would also lead to interesting analogs, and this effort is described 
below.   
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Figure 2.11. mGluR5 NAM HTS hit and early analogs.41 
 
 
 
 
 
Figure 2.12. mGluR5 NAM tool compound VU0409106 (2.15). 
 
 
 
 The first SAR endeavor from 2.13 was heteroaryl substitution of the phenyl core. 
These analogs were created through one of two different routes.38 In Route I, e.g. Scheme 
2.1, coupling of a commercially available haloheteroarylamine (2.16) with a carboxylic 
acid (2.17) or acid chloride afforded the amide intermediate (2.18).  Nucleophilic 
aromatic substitution (SNAR) with 3-hydroxypyridine (2.19) under basic conditions 
provided the biaryl ether analog (2.20).  In Route II, e.g. Scheme 2.2, formation of the 
ether occurred first via SNAR substitution of a dihalo-heteroaryl compound (2.21) with 3-
hydroxypyridine (2.19).  The ether (2.22) was then subjected to a palladium catalyzed 
coupling with a primary amide (2.23) to give the desired analog (2.24).  
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Scheme 2.1. Representative example of heteroaryl substitution of the phenyl core  
via Route I. 
 
 
 
 
 
Scheme 2.2. Representative example of heteroaryl substitution of the phenyl core  
via Route II. 
 
 
 
 Table 2.2 shows the heteroaryl substitution library.  Potency data in the primary 
assay is presented here as both pIC50 and IC50 values for convenient evaluation of SAR.  
Approximately half of the chemotype modifications exhibited a great decrease in 
potency.  Interestingly, derivatives 2.25 and 2.27 were five-fold less potent than 2.13, 
however, the combination of these substitutions yielded pyrazine 2.24 with ample 
activity.  We anticipated that optimization of 2.24 might restore lost potency, thus we 
continued SAR exploration from this analog.  A large change in potency was observed  
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Table 2.2. Heteroaryl core SAR 
                           
 
Cmpd R mGluR5 pIC50  (± SEM)a  
mGluR5 IC50 
(nM) 
% Glu Max  
(± SEM)a,b 
2.25 
 
6.39 ± 0.07  403 1.11 ± 0.40 
2.24 
 
6.89 ± 0.04 129 0.99 ± 0.33 
2.26 
 
5.43 ± 0.26 3699 -4.99 ± 4.65 
2.27 
 
6.44 ± 0.19 359 1.99 ± 0.74 
2.20 
 
6.00 ± 0.21 994 1.79 ± 0.70  
2.28 
 
<5.0c >10,000 44.08 ± 7.74  
2.29 
 
5.53 ± 0.23 2928 1.13 ± 0.54 
a Calcium mobilization mGluR5 assay; values are average of n ≥ 3 
b Amplitude of response in the presence of 30 µM test compound as a percentage of maximal 
response (100 µM glutamate); average of n ≥ 3 
c CRC does not plateau 
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with the minor structural modification from pyrazine 2.24 to pyrimidine 2.28.  This type 
of observation, nonetheless, can often be the case in allosteric modulator chemotypes.41 
 Next, with the optimized pyrazine core in hand, we evaluated modifications of the 
northern pyridine ether using “head groups” known to increase potency in similar 
mGluR5 NAMs of this chemotype.  Preparation of these analogs followed the general 
methods outlined in Scheme 2.3.  SNAR substitution of one of the chlorine atoms in 2,6-
dichloropyrazine (2.21) with either 5-fluoropyridin-3-ol or pyrimidin-5-ol (2.30) under 
basic conditions provided ether intermediate 2.31.  Palladium catalyzed coupling of 2.31 
with tert-butyl carbamate (2.32) afforded carbamate 2.33.  The amine was liberated by 
treatment with acid and was then coupled to a carboxylic acid via Kraus and co-workers 
2005 procedure to yield substituted heteroarylamine carboxamide analogs (2.35).44 
 
 
    
 
Scheme 2.3. Preparation of substituted heteroarylamine carboxamides (2.35).  
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 Table 2.3 shows the library of compounds tested with the fluoropyridine ether 
motif.  Most of these substitutions were not tolerated, including those with five-
membered ring heteroaryls.  Analog 2.43, prepared with 3-chlorobenzoic acid as in the 
lead compound, exhibited enhanced potency with the fluoropyridine head group.  
Compound 2.47, prepared with 3-methylbenzoic acid, was also moderately potent.  
Preparations with the corresponding picolinic acids afforded analog 2.36 and 2.37, 
respectively.  While the potency of 2.37 decreased compared to the benzoic acid analog, 
2.36 exhibited a slight increase in potency from 2.43.  
 
 
Table 2.3. Northern fluoropyridine SAR 
 
 
Cmpd R mGluR5 pIC50 (± SEM)a 
mGluR5 IC50  
(nM) 
% Glu Max  
(± SEM)a,b 
2.36 
 
6.95 ± 0.29 111 1.95 ± 0.26 
2.37 
 
6.51 ± 0.15 311 1.70 ± 0.39 
2.38 
 
5.20 ± 0.11 6370 7.77 ± 2.80 
2.39 
 
5.46 ± 0.15 3453 0.06 ± 2.37 
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Table 2.3. continued 
 
Cmpd R mGluR5 pIC50 (± SEM)a 
mGluR5 IC50  
(nM) 
% Glu Max  
(± SEM)a,b 
2.40 
 
5.07 ± 0.05 8425 22.27 ± 11.40 
2.41 
 
<4.5 >30,000 -  
2.42 
 
<5.0c >10,000 52.16 ± 10.51 
2.43 
 
6.93 ± 0.10 118 1.96 ± 0.32 
2.44 
 
5.42 ± 0.09 3824 -0.37 ± 1.69 
2.45 
 
6.18 ± 0.16 662 1.20 ± 0.29 
2.46 
 
5.36 ± 0.17 4397 -5.63 ± 5.06 
2.47 
 
6.70 ± 0.18 199 2.08 ± 0.35 
2.48 
 
<4.5 >30,000 - 
2.49 
 
5.34 ± 0.15 4585 -2.80 ± 6.19 
2.50 
 
6.05 ± 0.13 894 1.01 ± 0.75 
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Table 2.3. continued 
 
Cmpd R mGluR5 pIC50 (± SEM)a 
mGluR5 IC50  
(nM) 
% Glu Max  
(± SEM)a,b 
2.51 
 
<4.5 >30,000 - 
2.52 
 
5.18 ± 0.18 6596 6.63 ± 2.02 
2.53 
 
<4.5 >30,000 - 
2.54 
 
<4.5 >30,000 - 
2.55 
 
<4.5 >30,000 - 
2.56 
 
<4.5 >30,000 - 
2.57 
 
<4.5 >30,000 - 
2.58 
 
<4.5 >30,000 - 
2.59 
 
<4.5 >30,000 - 
2.60 
 
5.23 ± 0.13 5933 1.59 ± 1.95 
2.61 
 
<5.0c >10,000 39.71 ± 15.28 
F
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Table 2.3. continued 
 
Cmpd R mGluR5 pIC50 (± SEM)a 
mGluR5 IC50  
(nM) 
% Glu Max  
(± SEM)a,b 
2.62 
 
<4.5 >30,000 - 
2.63 
 
<4.5 >30,000 - 
2.64 
 
<4.5 >30,000 - 
2.65 
 
<4.5 >30,000 - 
2.66 
 
<4.5 >30,000 - 
2.67 
 
6.00 ± 0.04 990 1.10 ± 0.75 
2.68 
 
<5.0c >10,000 47.94 ± 9.54 
2.69 
 
<5.0c >10,000 39.75 ± 9.28 
2.70 
 
5.06 ± 0.09 8646 -9.42 ± 2.26 
2.71 
 
<5.0c >10,000 35.99 ± 8.34 
2.72 
 
5.33 ± 0.17 4642 18.85 ± 6.13 
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Table 2.3. continued 
 
Cmpd R mGluR5 pIC50 (± SEM)a 
mGluR5 IC50  
(nM) 
% Glu Max  
(± SEM)a,b 
2.73 
 
<5.0c >10,000 20.22 ± 10.44 
2.74 
 
<4.5 >30,000 - 
a Calcium mobilization mGluR5 assay; values are average of n ≥ 3 
b Amplitude of response in the presence of 30 µM test compound as a percentage of maximal response 
(100 µM glutamate); average of n ≥ 3 
c CRC does not plateau 
 
 
 
 Further exploration with a pyrimidine head group (Table 2.4) gave similar results.  
Many analogs were inactive in our primary assay, and the active compounds were those 
with substitutions at the 3-position with or without the picolinic nitrogen.  Again, analog 
2.11 (VU0431316), with the 3-chloropicolinic acid, proved to be the most potent 
compound, exhibiting an IC50 of 62 nM.  This compound was further characterized and 
studied in a variety of in vitro and in vivo assays, ultimately becoming tool compound 
VU0431316.  Figure 2.13 shows the relevant fold-shift data for this compound via the 
calcium mobilization assay previously described.  A detailed description of this assay can 
be found in the literature.45 
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Table 2.4. Northern pyrimidine SAR 
 
 
Cmpd R mGluR5 pIC50 (± SEM)a 
mGluR5 IC50  
(nM) 
% Glu Max  
(± SEM)a,b 
2.11 
(VU0431316) 
 
7.20 ± 0.06 62 1.58 ± 0.10 
2.75 
 
6.94 ± 0.10 116 1.24 ± 0.04 
2.76 
 
6.15 ± 0.17 709 1.48 ± 0.22 
2.77 
 
<4.5 >30,000 - 
2.78 
 
6.67 ± 0.16 212 1.52 ± 0.50 
2.79 
 
6.72 ± 0.22 193 2.10 ± 0.79 
2.80 
 
7.00 ± 0.29 100 2.26 ± 0.56 
2.81 
 
<5.0c >10,000 15.24 ± 8.21 
2.82 
 
<5.0c >10,000 35.34 ± 6.43 
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Table 2.4. continued 
Cmpd R mGluR5 pIC50 (± SEM)a 
mGluR5 IC50  
(nM) 
% Glu Max  
(± SEM)a,b 
2.83 
 
<5.0c >10,000 20.50 
2.84 
 
<4.5 >30,000 - 
2.85 
 
5.29 ± 0.17 5138 1.48 ± 2.73 
2.86 
 
5.39 ± 0.15 4111 -4.32 ± 2.68 
2.87 
 
<5.0c >10,000 11.99 ± 11.06 
a Calcium mobilization mGluR5 assay; values are average of n ≥ 3 
b Amplitude of response in the presence of 30 µM test compound as a percentage of maximal response 
(100 µM glutamate); average of n ≥ 3 
c CRC does not plateau 
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Figure 2.13. Fold shift data for 2.11 (VU0431316). 
 
 
 
2.4.2. Drug Metabolism and Pharmacokinetics 
 
 Measuring intrinsic clearance in rodent and human liver microsomes is an 
important assay in which to assess cytochrome P450 metabolism.  Table 2.5 shows 2.11’s 
(VU0431316’s) CYP profile, with the only concern being CYP1A2.  Protein binding 
(Table 2.6) estimates how much free drug there is available to interact with the receptor.  
Using methods developed by Kalvass and Maurer, nonspecific binding to rodent brain 
homogenates (BHB) with 2.11 (VU0431316) showed good free fraction, which was 
expected with the low lipophilic compound (cLogP = 0.84; calculated using ADRIANA. 
Code (www.molecular-networks.com)).46  
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Table 2.5. CYP450 inhibition 
 
CYP IC50 (µM) 
3A4 ≥ 30 
2D6 >30 
2C9 >30 
1A2 0.64 
2C19 >30 
 
 
 
Table 2.6. Protein binding 
 
Protein Binding % Bound 
Human PPB 91.0 
Mouse BHB 94.6 
 
 
 
 Previous in house studies with the northern pyrimidine ethers have indicated a 
major role of nonP450-mediated metabolism.  In 2012, Morrison et al. published on the 
aldehyde oxidase metabolism of 2.15 (VU0409106), fully elucidating and characterizing 
this metabolic pathway.47 Scheme 2.4 and Figure 2.14 show that 2.11 (VU0431316) is 
subject to aldehyde oxidase metabolism to metabolite M1.   
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Scheme 2.4. Aldehyde oxidase metabolism of 2.11 (VU0431316). 
 
 
 
 
Figure 2.14. Compound 2.11 (VU0431316) liver S9 fraction incubation. 
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2.4.3.   Behavioral Pharmacology 
 Because of its promising potency, in vitro data, and rat pharmacokinetic (PK) 
profile (data not shown), compound 2.11 (VU0431316) was deemed appropriate to test in 
an acute behavioral study in mice.   Prior to this study, it was imperative to better 
understand the molecular pharmacology of 2.11 (VU0431316).   Competition binding 
experiments with [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine ([3H]mPEPy), a close 
structural analog of MPEP (2.3), were completed by determining the inhibition of this 
compound with 2.11 (VU0431316).  This study confirmed that 2.11 (VU0431316) 
inhibits [3H]mPEPy and, therefore, binds at the known mGluR5 allosteric site (mGluR5 Ki 
= 37 nM) (Figure 2.15, data for 2.15 (VU0409106) also shown).   
 Mice are known to bury both harmless and noxious objects, and it was suggested 
that the burying of glass marbles could be a useful behavioral test for anxiolytic 
activity.48,49 In 1986, Broekkamp et al. demonstrated that dosing mice with a variety of 
anxiolytic compounds differentially inhibited marble burying.49 Njung'e and Handley 
later proposed that marble burying may actually be a correlation test of anxiety; that is, 
modeling a different behavior that is affected by anxiolytic compounds.48 More recent 
data indicates that mice might not be deliberately burying marbles but rather that the 
marbles fall through the displaced bedding.50 Nevertheless, this behavioral assay studies 
the digging behavior of mice and is accepted as a convenient and rapid means to probe 
hippocampal function.  MPEP (2.3) and fenobam (2.8) are effective in this model as is 
2.15 (VU0409106).41 
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Figure 2.15. Compounds 2.15 (VU0409106) and 2.11 (VU0431316) binding studies. 
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 The marble burying paradigm was performed with naïve mice.  A dose response 
study using intraperitoneal (IP) dosing of 2.11 (VU0431316) was conducted using a 15-
minute pretreatment.  Dose-dependent inhibition was observed with no noticeable 
sedation within the dose range tested (Figure 2.16).  The median effective dose (ED50), 
for 2.11 (VU0431316) was determined to be 6.6 mg/kg.  For a more detailed 
experimental procedure, see Lindsley 2011.51 
 
 
 
n = 7-8 per dose; *P < 0.05 versus vehicle control group, Dunnett’s test.  
 
Figure 2.16. Dose dependent inhibition of marble burying with 2.11 (VU0431316).  
 
 
 
2.5. Conclusions and Future Directions 
 
 In summary, substantial SAR was developed in a heteroarylamine carboxamide 
series of mGluR5 NAMs leading to identification of tool compound 2.11 (VU0431316).  
This compound is a potent noncompetitive antagonist that binds at the known allosteric 
site of mGluR5.  Compound 2.11 (VU0431316) proved efficacious in a mouse marble 
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burying model of anxiety, an assay known to be sensitive to mGluR5 NAMs.  
Forthcoming in vivo experiments with this compound include behavioral assays of other 
mGluR5 diseases and monkey PK studies.     
 
 
2.6. Experimental Section 
 
 
 
2.6.1. Methods and Materials 
 
     All reagents and solvents were commercial grade and purified prior to use when 
necessary. Analytical TLC was performed on Sorbent Technologies HL 0.25 mm silica 
gel plates with UV indicator. Visualization was accomplished by irradiation under a 254 
nm UV lamp and/or the use of an iodine chamber. Chromatography on silica gel was 
performed using Silica Gel 60 (230-400 mesh) from Sorbent Technologies. 
   1H NMR spectra were recorded on a Bruker DRX-400 (400 MHz) NMR 
instrument. Chemical shifts are reported in ppm from the solvent resonance as an internal 
standard. Data are reported as follows: chemical shift, multiplicity, coupling constant 
(Hz), and number of protons. 
 
 
2.6.2. Selected Experimental Procedures 
 
 
 
 
 
3-chloro-N-(4-chloropyridin-2-yl)benzamide (2.18).  2-amino-4-chloropyridine (90 
mg, 0.70 mmol, 1.1 eq), 3-chlorobenzoic acid (0.1 mg, 0.6 mmol, 1 eq), 1-ethyl-3-(3-
N
Cl
N
H
O
Cl
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dimethylaminopropyl) carbodiimide (135 mg, 0.704 mmol, 1.10 eq) and 4-
dimethylaminopyridine (7.8 mg, 0.064 mmol, 0.10 eq) were dissolved in CH2Cl2 (5 mL) 
and stirred at rt overnight.  Water was added and the layers separated.  The organic layer 
was dried (MgSO4), filtered and concentrated in vacuo.  Purification by flash 
chromatography on silica gel afforded 160 mg (94%) of the title compound as a white 
solid:  1H NMR (400 MHz, DMSO-d6) δ 11.21 (s, 1H), 8.39 (d, J = 5.4 Hz, 1H), 8.27 (d, 
J = 1.6 Hz, 1H), 8.06 (t, J = 1.8 Hz, 1H), 7.96 (dt, J = 7.6, 1.2 Hz, 1H), 7.67 (ddd, J = 8.0, 
2.1, 1.0 Hz, 1H), 7.54 (t, J = 7.9 Hz, 1H), 7.32 (dd, J = 5.4, 2.0 Hz, 1H); ES-MS 
[M+1]+:267.1. 
 
 
 
3-chloro-N-4-(pyridin-3-yloxy)pyridin-2-yl)benzamide (2.20).  Compound 2.18 (50 
mg, 0.19 mmol, 1.0 eq) 3-hydroxypyridine (26.7 mg, 0.281 mmol, 1.50 eq), CuI (3.7 mg, 
0.019 mmol, 0.10 eq) Cs2CO3 (122 mg, 0.374 mmol, 2.00 eq) and N,N-dimethylglycine 
hydrochloride (7.8 mg, 0.056 mmol, 0.30 eq) were dissolved in 1,4-dioxane (1 mL) in a 
flame-dried sealed tube and heated overnight at 90 °C.  The reaction was cooled to rt, 
plugged through celite and concentrated.  Purification by flash chromatography on silica 
gel afforded 24 mg (40%) of the title compound as a pale yellow oil:  chromatography on 
silica gel afforded 160 mg (94%) of the title compound as a white solid:  1H NMR (400 
MHz, DMSO-d6) δ 11.06 (s, 1H), 8.55-8.53 (m, 2H), 8.31 (d, J = 5.7 Hz, 1H), 8.01 (m, 
1H), 7.92 (d, J = 7.8 Hz, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.73 (ddd, J = 8.4, 2.6, 1.2 Hz, 
N
O
N
H
O
Cl
N
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1H), 7.64 (d, J = 8.6 Hz, 1H), 7.55 (dd, J = 8.4, 4.7 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 
6.82 (dd, J = 5.7, 2.4 Hz, 1H); ES-MS [M+1]+:326.1. 
 
 
 
2-chloro-6-(pyridin-3-yloxy)pyrazine (2.22). 2,6-dichloropyrazine (1.0 g, 6.7 mmol, 1.0 
eq), 3-hydroxypyridine (638 mg, 6.71 mmol, 1.00 eq) and K2CO3 (1.11 g, 8.03 mmol, 
1.20 eq) were dissolved in DMF (10 mL) and heated in a microwave for 15 minutes at 
150 °C.  The reaction was cooled, diluted with EtOAc and washed with H2O (3x).  The 
organic layer was dried (MgSO4), filtered, and concentrated in vacuo.  Purification by 
flash chromatography on silica gel afforded 1.3 g (93%) of the title compound as a white 
solid:  1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 2.3 Hz, 1H), 8.56 (d, J = 4.4 Hz, 1H), 
8.41 (s, 1H), 8.37 (s, 1H), 7.71 (dq, J = 8.4, 1.3 Hz, 1H), 7.51 (dd, J = 8.4, 4.9 Hz, 1H); 
ES-MS [M+1]+: 208.1. 
 
 
 
3-chloro-N-(6-pyridin-3-yloxy)pyrazin-2-yl)benzamide (2.24).  Compound 2.22 (944 
mg, 4.55 mmol, 1.00 eq), 3-chlorobenzamide (1.06 g, 6.81 mmol, 1.50 eq), NaOt-Bu 
(612 mg, 6.37 mmol, 1.40 eq), Pd(OAc)2 (51 mg, 0.23 mmol, 0.050 eq) and Xantphos 
(263 mg, 0.455 mmol, 0.100 eq) were dissolved in toluene (9.4 mL) in a flame-dried 
N
O
N
N
Cl
N
O
N
N
N
H
O
Cl
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sealed tube and heated at 110 °C for 18h.  The reaction was cooled to rt, diluted with 
CH2Cl2 and filtered through a plug of celite.  Purification by flash chromatography on 
silica gel afforded 1.08 g (73%) of the title compound as a white solid:  1H NMR (400 
MHz, DMSO-d6) δ 11.07 (s, 1H), 9.17 (s, 1H), 8.59 (d, J = 2.7 Hz, 1H), 8.46 (dd, J = 4.7, 
1.2 Hz, 1H), 8.33 (s, 1H), 8.00 (t, J = 1.8 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.77 (ddd, J = 
8.4, 2.8, 1.4 Hz, 1H), 7.67-7.64 (m, 1H), 7.54-7.48 (m, 2H); ES-MS [M+1]+: 327.1. 
 
 
2-chloro-6-((5-fluoropyridin-3-yl)oxy)pyrazine (2.31a).  A mixture of 2,6-
dichloropyrazine (4.0 g, 27 mmol, 1.0 eq), 5-fluoropyridin-3-ol (3.0 g, 27 mmol, 1.0 eq), 
and potassium carbonate (5.6 g, 40 mmol, 1.5 eq) in DMF (80 mL) was microwaved at 
120 °C for 10 minutes.  The reaction was diluted with CH2Cl2 and washed with H2O (3x) 
and brine (1x).  The organic layer was dried (MgSO4), filtered, and concentrated in 
vacuo.  The crude product was diluted in toluene, concentrated onto silica gel, and 
washed with EtOAc.  The filtrate was collected and concentrated in vacuo.  Purification 
by flash chromatography on silica gel (25:75 EtOAc/hexanes) afforded 3.8 g (62%) of the 
title compound as a white solid.  1H NMR (400 MHz, DMSO-d6) δ 8.68 (s, 1H), 8.61 (s, 
1H), 8.58 (d, J = 2.4 Hz, 1H), 8.52 (d, J = 1.1 Hz, 1H), 7.95 (dt, J = 9.8, 2.4 Hz, 1H); ES-
MS [M+1]+: 226.1. 
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tert-butyl (6-((5-fluoropyridin-3-yl)oxy)pyrazin-2-yl)carbamate (2.33a).  Compound 
2.31a (1.0 g, 4.0 mmol, 1.0 eq), tert-butyl carbamate (623 mg, 5.32 mmol, 1.20 eq), tris 
(dibenzylideneacetone) dipalladium-chloroform adduct (138 mg, 0.130 mmol, 0.0300 
eq), sodium tert-butoxide (596 mg, 6.21 mmol, 1.40 eq), and 2-di-tert-butylphosphino-
2’,4’,6’-triisopropylbiphenyl (199 mg, 0.400 mmol, 0.0900 eq) stirred in toluene (17 mL) 
at rt overnight.  The mixture was filtered through celite and washed with 5% MeOH in 
CH2Cl2.  The filtrate was collected and concentrated in vacuo.  Purification by flash 
chromatography on silica gel (30:70 EtOAc/hexanes) afforded 870 mg (64%) of the title 
compound as a white solid.   
 
 
6-((5-fluoropyridin-3-yl)oxy)pyrazin-2-amine (2.34a).  Compound 2.33a (120 mg, 
0.390 mmol, 1.00 eq) was stirred in 4M HCl in dioxane (1.90 mL) at rt overnight.  The 
reaction mixture was concentrated in vacuo to give quantitative yield of the title 
compound as a pink HCl salt.  1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J = 2.4 Hz, 1H), 
8.38 (s, 1H), 7.77 (dt, J = 10.1, 2.3 Hz, 1H), 7.65 (s, 1H), 7.56 (s, 1H), 7.16 (t, J = 51.0 
Hz, 2H); ES-MS [M+1]+: 207.1. 
N
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4-chloro-N-(6-((5-fluoropyridin-3-yl)oxy)pyrazin-2-yl)picolinamide (2.36). 
Compound 2.34a (1.0 eq) and 4-chloropicolinic acid (1.1 eq) were dissolved in pyridine 
(0.08 M reaction c) and cooled to -15 °C.  Phosphorus oxychloride (1.1 eq) was added 
dropwise.  The resulting reaction mixture was stirred at -15 °C for 30 minutes.  The 
reaction was quenched with ice water, warmed to rt, and allowed to stir overnight.  The 
reaction was diluted in CH2Cl2, and the layers were separated via phase separation.  The 
organic layer was dried on air concentrator and purified by reverse-phase preparatory 
HPLC to afford the title compound.  1H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 
9.23 (s, 1H), 8.70 (d, J = 5.3 Hz, 1H), 8.56-8.55 (m, 2H), 8.45 (s, 1H), 8.19 (d, J = 1.9 
Hz, 1H), 7.99 (dt, J = 10.0, 2.4 Hz, 1H), 7.88 (dd, J = 5.3, 2.1 Hz, 1H); ES-MS [M+1]+: 
346.1. 
 
 
5-((6-chloropyrazin-2-yl)oxy)pyrimidine (2.31b).  A mixture of 2,6-dichloropyrazine 
(500 mg, 3.36 mmol, 1.00 eq), pyrimidin-5-ol (320 mg, 3.36 mmol, 1.00 eq), and 
potassium carbonate (696 mg, 5.03 mmol, 1.50 eq) in DMF (10.0 mL) was microwaved 
at 120 °C for 10 minutes.  The reaction was diluted with CH2Cl2 and washed with H2O 
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(3x) and brine (1x).  The organic layer was dried (MgSO4), filtered, and concentrated in 
vacuo.  Purification by flash chromatography on silica gel (30:70 EtOAc/hexanes) 
afforded 220 mg (31%) of the title compound as an off-white solid.  1H NMR (400 MHz, 
DMSO-d6) δ 9.15 (s, 1H), 8.93 (s, 2H), 8.73 (s, 1H), 8.62 (s, 1H); ES-MS [M+1]+: 209.1. 
 
 
tert-butyl (6-(pyrimidin-5-yloxy)pyrazin-2-yl)carbamate (2.33b).  Compound 2.31b 
(400 mg, 1.92 mmol, 1.00 eq), tert-butyl carbamate (270 mg, 2.30 mmol, 1.20 eq), tris 
(dibenzylideneacetone) dipalladium-chloroform adduct (60 mg, 0.060 mmol, 0.030 eq), 
sodium tert-butoxide (258 mg, 2.68 mmol, 1.40 eq), and 2-di-tert-butylphosphino-
2’,4’,6’-triisopropylbiphenyl (86 mg, 0.17 mmol, 0.090 eq) stirred in toluene (7.2 mL) at 
rt overnight.  The mixture was filtered through celite and washed with 5% MeOH in 
CH2Cl2.  The filtrate was collected and concentrated in vacuo.  Purification by flash 
chromatography on silica gel (40:60 EtOAc/hexanes) afforded 240 mg (43%) of the title 
compound as a light yellow solid.  1H NMR (400 MHz, DMSO-d6) δ 10.14 (s, 1H), 9.09 
(s, 1H), 8.91 (s, 2H), 8.82 (s, 1H), 8.25 (s, 1H), 1.45 (s, 9H); ES-MS [M+1]+: 290.1. 
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6-(pyrimidin-5-yloxy)pyrazin-2-amine (2.34b).  Compound 2.33b (480 mg, 1.66 mmol, 
1.00 eq) was stirred in 4:1 CH2Cl2:TFA (2.00 mL) at rt overnight.  The reaction mixture 
was concentrated in vacuo and diluted in EtOAc.  The organic layer was washed with 
saturated NaHCO3 (3x) and brine (1x), dried (MgSO4), filtered and concentrated in vacuo 
to give 300 mg (96%) of the title compound as an orange solid.  1H NMR (400 MHz, 
DMSO-d6) δ 9.04 (s, 1H), 8.79 (s, 2H), 7.65 (s, 1H), 7.60 (s, 1H), 6.64 (s, 2H); ES-MS 
[M+1]+: 190.1. 
 
 
4-chloro-N-(6-(pyrimidin-5-yloxy)pyrazin-2-yl)picolinamide (2.11, VU0431316).  
Compound 2.34b (1.0 eq) and 4-chloropicolinic acid (1.1 eq) were dissolved in pyridine 
(0.08 M reaction c) and cooled to -15 °C.  Phosphorus oxychloride (1.1 eq) was added 
dropwise.  The resulting reaction mixture was stirred at -15 °C for 30 minutes.  The 
reaction was quenched with ice water, warmed to rt, and allowed to stir overnight.  The 
reaction was diluted in CH2Cl2, and the layers were separated via phase separation.  The 
organic layer was dried on air concentrator and purified by reverse-phase preparatory 
HPLC to afford the desired product.  1H NMR (400 MHz, DMSO-d6) δ 10.64 (s, 1H), 
N
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9.24 (s, 1H), 9.14 (s, 1H), 8.99 (s, 2H), 8.71 (d, J = 5.3 Hz 1H) 8.50 (s, 1H), 8.19 (d, J = 
1.8 Hz, 1H), 7.89 (dd, J = 5.3, 2.0 Hz, 1H); ES-MS [M+1]+: 329.1. 
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Appendix A 
 
 
 
SPECTRA RELEVANT TO CHAPTER 1 
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Appendix B 
 
 
SPECTRA RELEVANT TO CHAPTER 2 
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